NCT01514123View on ClinicalTrials.gov

Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 29, 2011

Primary Completion Date

February 7, 2014

Study Completion Date

November 16, 2017

Conditions
NeoplasmsCancer
Interventions
DRUG

VGX-100

VGX-100 will be administered by IV infusion once every week

DRUG

Bevacizumab

Bevacizumab will be administered by IV infusion once every 2 weeks

Trial Locations (2)

77030

UT MD Anderson Cancer Center, Houston

90404

UCLA Hematology-Oncology, Santa Monica

Sponsors
All Listed Sponsors
lead

Circadian Technologies Ltd.

INDUSTRY